Dana-Farber Cancer Institute

This is your central portal for breaking news, the latest research and important updates from Dana-Farber Cancer Institute. Bookmark this page and check back often for updates.

Meeting NewsPerspective

Novel small-molecule inhibitor ‘quite promising’ in advanced kidney cancer

February 18, 2020
MK-6482 appeared well-tolerated and showed promising single-agent activity among heavily pretreated patients with clear cell renal cell carcinoma…

Foundation presents grants to six early career cancer researchers

February 9, 2020
The Mark Foundation for Cancer Research presented grants to six early career scientists who are conducting research projects designed to address…
Feature

Many US women eligible for breast-conserving therapy still opt for mastectomy

February 4, 2020
Breast-conserving therapy, also known as lumpectomy, followed by radiation has been shown to be as effective as mastectomy for most women with breast…
Meeting NewsPerspective

Blood test could lead to earlier detection of gastrointestinal cancers

January 24, 2020
An investigational blood-based assay demonstrated efficacy in detecting multiple types of cancer, including gastrointestinal cancers, at various…
Point/Counter

Will liquid biopsies be used routinely to screen for cancer?

HemOnc Today, January 25, 2020
POINT Genomic analysis of plasma cfDNA has been adopted widely in the care of patients with cancer. Indeed, the rapid and widespread adoption is striking…
Feature

Minority patients value, but are less likely to see, oncologists who understand their culture

January 8, 2020
The existence of racial

AACR-MPM Oncology Charitable Foundation awards grants to cancer researchers

January 2, 2020
American Association for Cancer Research and MPM Capital awarded two grants that will provide a combined $800,000 for cancer research. These are the…

ASH presents Scholar Awards to fellows, junior faculty

December 22, 2019
ASH announced the recipients of its 2019 Scholar Awards. The awards — presented to hematologists in the United States and Canada who conduct…
Meeting News

Melflufen, dexamethasone demonstrate long-term OS benefits in multiple myeloma

December 13, 2019
ORLANDO — Treatment with melflufen and dexamethasone led to sustained long-term overall survival among patients with relapsed/refractory…
Meeting NewsPerspective

Ado-trastuzumab emtansine extends DFS in early-stage HER2-positive breast cancer

December 12, 2019
SAN ANTONIO — Ado-trastuzumab emtansine extended DFS compared with paclitaxel plus trastuzumab among patients with early-stage HER2-positive…
Meeting NewsPerspective

Antibody-drug conjugate provides ‘unprecedented’ benefit in metastatic HER2-positive breast cancer

December 11, 2019
SAN ANTONIO — Trastuzumab deruxtecan conferred durable benefit to women with heavily pretreated HER2-posiive metastatic breast cancer…
Meeting News

Allogeneic HSCT after PD-1 therapy safe, effective in Hodgkin lymphoma

December 9, 2019
ORLANDO — Allogeneic hematopoietic stem cell transplantation appeared effective and generally safe for patients with relapsed or refractory…
Meeting News

ASH acknowledges three Choosing Wisely Champions for their ‘elegant, implementable strategies’

December 9, 2019
ORLANDO — ASH named three Choosing Wisely Champions today at its Annual Meeting and Exposition, recognizing clinicians who have implemented…
Meeting News

Daratumumab regimen increases response in transplant-eligible multiple myeloma

December 9, 2019
ORLANDO — The addition of daratumumab to lenalidomide, bortezomib and dexamethasone significantly improved rates of stringent clinical response…
Meeting NewsPerspective

Three-agent regimen effective, safe in high-risk smoldering multiple myeloma

December 9, 2019
ORLANDO — The combination of ixazomib, lenalidomide and dexamethasone appeared highly effective for patients with high-risk smoldering myeloma…
Meeting NewsPerspective

Front-line acalabrutinib regimen appears safe, induces complete response in chronic lymphocytic leukemia

December 7, 2019
ORLANDO — The combination of acalabrutinib, venetoclax and obinutuzumab demonstrated high rates of complete response and undetectable minimal…
Meeting NewsPerspective

Genetic alterations at diagnosis predict transplant outcomes for older patients with AML

December 7, 2019
ORLANDO — Genetic alterations at diagnosis predicted OS and leukemia-free survival for older individuals with acute myeloid leukemia who…
FDA News

FDA grants Orencia breakthrough therapy designation to prevent acute GVHD

December 4, 2019
The FDA granted breakthrough therapy designation to abatacept for prevention of moderate to severe acute graft-versus-host disease among individuals…
Meeting NewsPerspective

Novel blood tests could improve cancer detection

November 14, 2019
Two novel blood assays demonstrated efficacy in detecting various cancer types at different disease stages, according to results of two studies…
In the Journals

Pembrolizumab induces durable responses in relapsed, refractory primary mediastinal large B-cell lymphoma

November 14, 2019
Pembrolizumab appeared to be associated with high response rates, durable activity and manageable toxicity among patients with relapsed or refractory…